Becky McCall October 18, 2024 Added to Email Alert 012 VIENNA — Cendakimab, a monoclonal antibody targeting interleukin (IL) 13, improved symptoms and reduced esophageal eosinophil counts in adult and adolescent patients with eosinophilic esophagitis (EoE), according to interim results of a pivotal phase 3 trial. Treatment with cendakimab also improved key endoscopic and histologic features, even...
Tag: <span>eosinophilic esophagitis</span>
Post
Among allergic conditions, food allergy found to have highest risk of developing eosinophilic esophagitis
by American College of Allergy, Asthma, and Immunology Credit: Unsplash/CC0 Public Domain Eosinophilic esophagitis (EoE), a disorder of the esophagus, is increasingly recognized as a major cause of swallowing difficulties in children and adults. It affects about one in 2,000 people and is part of a spectrum of allergic conditions. A study presented at this year’s...
Post
How new drug approvals are reshaping treatment for eosinophilic esophagitis
by Morgan Duerden, University of North Carolina School of Medicine Credit: Pixabay/CC0 Public DomainEosinophilic esophagitis (EoE) is an allergic inflammatory disorder that affects the esophagus, causing distressing symptoms such as difficulty swallowing in adolescents and adults, and vomiting and abdominal pain in children. Evan Dellon, MD, MPH, a gastroenterologist at UNC Health and professor of medicine...
Post
New study finds forgoing one food may treat eosinophilic esophagitis as well as excluding six
by NIH/National Institute of Allergy and Infectious Diseases A glass of milk. Credit: NIAID Eliminating animal milk alone from the diet of adults with eosinophilic esophagitis (EoE) is as effective at treating the disease as eliminating animal milk plus five other common foods, a new clinical trial has found. For people with EoE whose disease...
Post
FDA approves first treatment for eosinophilic esophagitis
The U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Dupixent (dupilumab) to treat eosinophilic esophagitis patients 12 years and older. The efficacy and safety of Dupixent was evaluated in a randomized, double-blind, parallel-group (Part A and Part B), multicenter, placebo-controlled trial, in which patients received either placebo or Dupixent every week for 24...